Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Haemonetics (HAE) EPS (Basic) (2016 - 2025)

Haemonetics has reported EPS (Basic) over the past 17 years, most recently at $0.96 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 28.0% year-over-year to $0.96; the TTM value through Dec 2025 reached $3.65, up 42.58%, while the annual FY2025 figure was $3.33, 43.53% up from the prior year.
  • EPS (Basic) for Q4 2025 was $0.96 at Haemonetics, up from $0.81 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $1.17 in Q1 2025 and troughed at -$0.22 in Q2 2021.
  • A 5-year average of $0.55 and a median of $0.64 in 2022 define the central range for EPS (Basic).
  • Biggest five-year swings in EPS (Basic): crashed 162.86% in 2021 and later skyrocketed 533.33% in 2022.
  • Year by year, EPS (Basic) stood at $0.29 in 2021, then surged by 124.14% to $0.65 in 2022, then decreased by 4.62% to $0.62 in 2023, then increased by 20.97% to $0.75 in 2024, then rose by 28.0% to $0.96 in 2025.
  • Business Quant data shows EPS (Basic) for HAE at $0.96 in Q4 2025, $0.81 in Q3 2025, and $0.71 in Q2 2025.